GlassScriptPhysician profile
Alida Askren
NPI 1225787013
$1,324.54
in general payments reported to CMS, 2019-2025
23 companies · $870 in 2025
The $870 reported for 2025 was more than what 84% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $35.24 · 2023: $29.34 · 2024: $390 · 2025: $870.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,289.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,289.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $226.88 | 2022-2025 | Mounjaro, Zepbound |
| Novo Nordisk INC | $176.58 | 2024-2025 | Rybelsus, Ozempic |
| Bayer Healthcare Pharmaceuticals INC. | $150.53 | 2024-2025 | |
| Madrigal Pharmaceuticals | $97.92 | 2024 | Rezdiffra |
| Exact Sciences Corporation | $96.74 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Glaxosmithkline, LLC. | $70.90 | 2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Sumitomo Pharma America, INC. | $55.68 | 2024-2025 | Gemtesa |
| Antares Pharma, INC. | $48.70 | 2025 | Xyosted |
| Averitas Pharma INC. | $39.78 | 2025 | Qutenza |
| Pfizer INC. | $38.32 | 2025 | |
| Esperion Therapeutics, INC. | $38.24 | 2024-2025 | Nexletol |
| Kowa Pharmaceuticals America, INC. | $33.14 | 2025 | Zoryve |
| Dexcom, INC. | $33.11 | 2024-2025 | Dexcom G6 Transmitter |
| Vanda Pharmaceuticals INC. | $31.56 | 2024 | Hetlioz, Fanapt |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $29.59 | 2025 | Xifaxan |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $26.63 | 2025 | Caplyta |
| Abbvie INC. | $23.03 | 2025 | |
| Xeris Pharmaceuticals, INC. | $21.51 | 2025 | Keveyis |
| Teva Pharmaceuticals USA, INC. | $20.27 | 2025 | Austedo Xr |
| Amgen INC. | $19.41 | 2025 | Evenity |
| Novartis Pharmaceuticals Corporation | $15.53 | 2025 | |
| Si-Bone, INC. | $15.29 | 2025 | |
| Medtronic, INC. | $15.20 | 2024 | Intellis Adaptivestim |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alida Askren listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.